{
  "meta": {
    "title": "Drugs_In_Obs",
    "url": "https://brainandscalpel.vercel.app/drugs-in-obs-65972fed.html",
    "scrapedAt": "2025-11-29T18:30:44.684Z"
  },
  "questions": [
    {
      "id": 18705,
      "choices": [
        {
          "id": 74780,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methyldopa and labetalol are contraindicated in pregnancy due to their teratogenic effects. </span></span></span></p>"
        },
        {
          "id": 74781,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methyldopa and labetalol are safe choices for the management of hypertension during pregnancy</span></span></span></p>"
        },
        {
          "id": 74782,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methyldopa is safe, but labetalol should be avoided during pregnancy</span></span></span></p>"
        },
        {
          "id": 74783,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methyldopa and labetalol can cause intrauterine growth restriction (IUGR) and should be used with caution.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old pregnant woman with a history of hypertension presents to the antenatal clinic for a routine check-up. She is currently 24 weeks pregnant, and her blood pressure is well controlled on a combination of methyldopa and labetalol. She is concerned about the potential risks of these medications to her unborn baby. Which of the following statements about the use of methyldopa and labetalol in pregnancy is correct?</span></span></span></p>",
      "unique_key": "Q3869757",
      "question_audio": null,
      "question_video": null,
      "map_id": 18474,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B. Methyldopa and labetalol are safe choices for the management of hypertension during pregnancy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let&#39;s go through each option:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Methyldopa and labetalol are contraindicated in pregnancy due to their teratogenic effects: <strong>This is Incorrect. </strong>They are not contraindicated in pregnancy. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;Methyldopa and labetalol are safe choices for the management of hypertension during pregnancy: <strong>This is Correct</strong>. Methyldopa and labetalol are commonly used antihypertensive medications during pregnancy because they have a well-established safety profile for both the mother and the unborn baby.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Methyldopa is safe, but labetalol should be avoided during pregnancy: This <strong>statement is Incorrect.</strong> Both methyldopa and labetalol are generally considered safe during pregnancy.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;Methyldopa and labetalol can cause intrauterine growth restriction (IUGR) and should be used with caution: <strong>This statement INCORRECT.</strong> The benefits of controlling maternal hypertension often outweigh the potential risks of IUGR when these medications are used.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-hypertensives in pregnancy:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">DOC in pregnancy</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Labetalol (Max oral dose 2400mg/d); can be given IV in emergencies (Max IV dose is 220 mg)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Alpha methyl dopa</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Greatest safety data available, 48 h for onset of action</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nifedipine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> CCB, short acting, oral (S/l is c/i) used in emergencies</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hydralazine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> for emergencies, IV</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Diuretics</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: only if pulmonary edema </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Beta blockers</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: long term use causes Growth restriction, not preferred</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ACE inhibitors and ARB</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Absolute c/I in pregnancy as they cause fetal renal anomalies</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 1846, Williams Obstetrics 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74781,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18709,
      "choices": [
        {
          "id": 74796,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nifedipine </span></span></span></p>"
        },
        {
          "id": 74797,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnesium sulfate</span></span></span></p>"
        },
        {
          "id": 74798,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Terbutaline</span></span></span></p>"
        },
        {
          "id": 74799,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Indomethacin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 34-year-old pregnant woman with a history of preterm labor is admitted to the hospital at 32 weeks gestation with regular uterine contractions. She is diagnosed with threatened preterm labor and tocolysis is initiated to delay delivery for corticosteroid administration for fetal lung maturity which among the following should not be used? </span></span></span></p>",
      "unique_key": "Q6520570",
      "question_audio": null,
      "question_video": null,
      "map_id": 18478,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D. Indomethacin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis and reduces uterine contractions. However, its use is contraindicated after 32 weeks gestation due to the risk of premature closure of the ductus arteriosus in the fetus, leading to potential fetal harm. Therefore, it should not be used for tocolysis in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let&#39;s look at the other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;<strong>Nifedipine</strong>: Nifedipine is a calcium channel blocker used for tocolysis in some cases of preterm labor. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;<strong>Magnesium sulfate</strong>: Magnesium sulfate is often used for tocolysis, but it is typically preferred when the primary goal is neuroprotection for the preterm infant rather than delaying delivery for corticosteroid administration.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;<strong>Terbutaline</strong>: Terbutaline is a beta-agonist that can be used for tocolysis, but it is not the first-line choice in this scenario when the main objective is to delay delivery for corticosteroid administration.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/01/screenshot-2024-01-01-112732.jpg\" style=\"height:778px; width:894px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 2094, Williams Obstetrics 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74799,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18714,
      "choices": [
        {
          "id": 74816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maternal hypotension</span></span></span></p>"
        },
        {
          "id": 74817,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fetal bradycardia </span></span></span></p>"
        },
        {
          "id": 74818,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uterine rupture </span></span></span></p>"
        },
        {
          "id": 74819,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cord Prolapse</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman is in active labor at 40 weeks gestation. Oxytocin is administered to augment her labor progress. Which of the following is NOT a potential adverse effect associated with the use of oxytocin in labor augmentation?</span></span></span></p>",
      "unique_key": "Q8649263",
      "question_audio": null,
      "question_video": null,
      "map_id": 18483,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D. Cord prolapse</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adverse effects of oxytocin:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/01/screenshot-2024-01-01-113149.jpg\" style=\"height:459px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let&#39;s look at each option: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Maternal hypotension:</strong> Oxytocin can sometimes cause maternal hypotension and tachycardia</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option B.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Fetal bradycardia</strong>: Fetal bradycardia (abnormally slow heart rate in the fetus) is a potential adverse effect of oxytocin administration. It can occur due to uterine hyperstimulation, which reduces fetal oxygen supply.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Uterine rupture</strong>: It is a rare but serious complication associated with oxytocin use, especially when the uterus becomes hyperstimulated. It can lead to a tear or rupture in the uterine wall, which poses significant risks to both the mother and the baby.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Cord prolapse:</strong> Cord prolapse occurs when the umbilical cord slips through the cervix and becomes compressed during labor. It is not directly related to the administration of oxytocin but is a potential obstetric emergency that can happen during labor.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adverse effects of oxytocin:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/01/screenshot-2024-01-01-113357.jpg\" style=\"height:456px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 1260, Williams Obstetrics 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74819,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18717,
      "choices": [
        {
          "id": 74828,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxytocin is discontinued if the number of contractions is &gt; 5 in a 10-minute period or &gt; 7 in a 15-minute period or with a persistent non-reassuring fetal heart rate pattern.</span></span></span></p>"
        },
        {
          "id": 74829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The uterus contracts within 3 to 5 minutes of beginning an oxytocin infusion, and a plasma steady state is reached in 40 minutes</span></span></span></p>"
        },
        {
          "id": 74830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When oxytocin is stopped, its concentration in plasma falls slowly because the half-life is long</span></span></span></p>"
        },
        {
          "id": 74831,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxytocin is started at doses of 0.5 &ndash; 1.5 mIU/ml and gradually increased to a maximum of 48mIU/ml</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 23y primi presents at 38 weeks with prelabor rupture of membranes. Her Bishop&rsquo;s score is 6 and she is induced with oxytocin. Which is incorrect regarding oxytocin?</span></span></span></p>",
      "unique_key": "Q2101812",
      "question_audio": null,
      "question_video": null,
      "map_id": 18486,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. When oxytocin is stopped, its concentration in plasma falls slowly because the half-life is long</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let&#39;s look at each option:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Oxytocin is discontinued if the number of contractions is &gt; 5 in a 10-minute period or &gt; 7 in a 15-minute period or with a persistent non-reassuring fetal heart rate pattern.: This statement is correct. Oxytocin is discontinued if there are excessive contractions or if there is a persistent non-reassuring fetal heart rate pattern to ensure the safety of the mother and the baby.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> The uterus contracts within 3 to 5 minutes of beginning an oxytocin infusion, and a plasma steady state is reached in 40 minutes: This statement is correct. Oxytocin typically starts to induce uterine contractions within a few minutes of administration, and it reaches a steady state in plasma relatively quickly.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: When oxytocin is stopped, its concentration in plasma falls slowly because the half-life is long: This statement is incorrect. Oxytocin has a very short half-life, typically in the range of 1-6 minutes. Therefore, its concentration in plasma drops rapidly after discontinuation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Oxytocin is started at doses of 0.5 &ndash; 1.5 mIU/ml and gradually increased to a maximum of 48mIU/ml: statement is generally accurate. Oxytocin is typically started at low doses and gradually increased to achieve the desired uterine contractions while avoiding excessive stimulation.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><span style=\"font-size:12.0pt\">: Oxytocin is used for labor induction and augmentation, and it should be administered with close monitoring of uterine contractions and fetal well-being. It has a rapid onset of action and short half-life, to ensure safe and effective use during labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxytocin is used for induction and augmentation of labor</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The goal of induction or augmentation is to effect uterine activity sufficient to produce cervical change and fetal descent, while avoiding development of a nonreassuring fetal status. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In general, oxytocin is discontinued if the number of contractions persists with a frequency of more than five in a 10-minute period or more than seven in a 15-minute period or with a persistent non-reassuring fetal heart rate pattern. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The uterus contracts within 3 to 5 minutes of beginning an oxytocin infusion, and a plasma steady state is reached in 40 minutes</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxytocin discontinuation nearly always rapidly lowers contraction frequency. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">When oxytocin is stopped, its concentration in plasma rapidly falls because the half-life is approximately 3 to 5 minutes. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Uterine response to oxytocin increases from 20 to 30 weeks&rsquo; gestation and rises rapidly at term. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Oxytocin Regimens:&nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/01/screenshot-2024-01-01-113912.jpg\" style=\"height:317px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Max dose: 48 mU/min</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page no 1263, Williams Obstetrics 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74830,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18720,
      "choices": [
        {
          "id": 74840,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is an intravaginal oxytocin release system</span></span></span></p>"
        },
        {
          "id": 74841,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is an intracervical oxytocin release system</span></span></span></p>"
        },
        {
          "id": 74842,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is an intravaginal PGE2 release system</span></span></span></p>"
        },
        {
          "id": 74843,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is an intracervical PGE2 release system</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is CORRECT regarding this?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/12/untitled-363.jpg\" style=\"height:232px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q2272865",
      "question_audio": null,
      "question_video": null,
      "map_id": 18489,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. This is an intravaginal PGE2 release system</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/12/untitled-363_GvFaj2c.jpg\" style=\"height:232px; width:300px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is an intra-vaginal Dinoprostone (PGE2) system</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It contains 10mg of PGE2 </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Available by the names Cervidil and Propess</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Used for cervical ripening/ induction of labor</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thin,</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> flat, rectangular polymeric wafer held within a small, white, mesh polyester sac </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The sac has a long-attached tail to allow easy removal from the vagina. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The insert provides slower release of medication&mdash;0.3 mg/hC</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cervidil is used as a single dose placed transversely in the posterior vaginal fornix. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Following insertion, the woman remains recumbent for at least 2 hours. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The insert is removed after 12 hours or with labor onset and at least 30 minutes before the administration of oxytocin.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;Since the active drug is encased in a mesh sac, one benefit is the ability for removal if fetal heart rate abnormalities or tachysystole develop.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thus, option C: &nbsp;This is an intravaginal PGE2 release system is correct. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/01/screenshot-2024-01-01-114242_lqllaB7.jpg\" style=\"height:228px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is an intra-vaginal PGE2 release system called Propess or Cervidil</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Intravaginal prostaglandin E2 (PGE2) release systems such as Cervidil are used in obstetrics to facilitate cervical ripening and induce labour when medically indicated.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 1251, Williams Obstetrics 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74842,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18722,
      "choices": [
        {
          "id": 74848,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxytocin</span></span></span></p>"
        },
        {
          "id": 74849,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta mimetics</span></span></span></p>"
        },
        {
          "id": 74850,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prostaglandins</span></span></span></p>"
        },
        {
          "id": 74851,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non Steroidal Anti Inflammatory drugs</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 23y primi presents for induction of labor at 41 weeks. Her cervix is unfavourable with a Bishop score of 4. You proceed with cervical ripening using the agent shown below. This medication belongs to which group of drug?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/12/untitled-364.jpg\" style=\"height:224px; width:300px\" /></span></span></p>",
      "unique_key": "Q7893809",
      "question_audio": null,
      "question_video": null,
      "map_id": 18491,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. Prostaglandins</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The likely drug shown is misoprostol (PGE1) which is available as a tablet</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs used for induction of labor are</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxytocin: Available as an injection (Given as an IV infusion)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Prostaglandins</span></span></span>\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PGE1 (misoprostol) &ndash; available as a tablet; given vaginally/ orally or sublingually</span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PGE2 (Dinoprostone) &ndash; available as an intra-cervical gel or as a vaginal insert or as an oral tablet</span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let us look at each option:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>Oxytocin</strong>: Oxytocin is used to induce and augment labour once the cervix is favourable. It stimulates uterine contractions during labour but is not typically used for cervical ripening.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">. Beta mimetics: Beta mimetics are a class of drugs that can be used for tocolysis in certain situations but are not typically used for cervical ripening.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>Prostaglandins</strong>: Prostaglandins are commonly used for cervical ripening and induction of labor in cases where the cervix is unfavorable, as described in the scenario.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):</strong> NSAIDs are not typically used for cervical ripening or labor induction. They are primarily used for pain relief and anti-inflammatory purposes.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><span style=\"font-size:12.0pt\">: Prostaglandins are a group of drugs used for cervical ripening and induction of labor when the cervix is unfavourable, helping to prepare the cervix for labor and delivery. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Drugs used for induction of labor are</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxytocin: Available as an injection (Given as an IV infusion)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Prostaglandins</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PGE1 (misoprostol) &ndash; available as a tablet; given vaginally/ orally or sublingually</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PGE2 (Dinoprostone) &ndash; available as an intra-cervical gel or as a vaginal insert or as an oral tablet</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: JB Sharma&rsquo;s Textbook of Obstetrics 2<sup>nd</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 74850,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18723,
      "choices": [
        {
          "id": 74852,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombocytopenia</span></span></span></p>"
        },
        {
          "id": 74853,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gastritis and bleeding</span></span></span></p>"
        },
        {
          "id": 74854,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal pulmonary HTN</span></span></span></p>"
        },
        {
          "id": 74855,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolonged patency of the ductus arteriosus</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is a neonatal consequence of in utero exposure to non-steroidal anti-inflammatory drugs?</span></span></span></p>",
      "unique_key": "Q4754213",
      "question_audio": null,
      "question_video": null,
      "map_id": 18492,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. Neonatal pulmonary HTN</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Explanation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Aspirin and other NSAIDs nonspecifically inhibit both cyclooxygenase 1 (COX-1), which is an enzyme critical to normal platelet function, and COX2, which mediates inflammatory response mechanisms. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NSAIDs are associated with </span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Early spontaneous abortions</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Small increased risk of cardiac malformations</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ductus arteriosus constriction (Esp if used &gt; 32 weeks)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Neonatal pulmonary hypertension</span></span></span><br />\r\n\t\t&nbsp;</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let us look at each option:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">. <strong>Thrombocytopenia</strong>: Thrombocytopenia (low platelet count) is not typically associated with in utero exposure to nonsteroidal anti-inflammatory drugs (NSAIDs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Gastritis and bleeding:</strong> In utero exposure to NSAIDs can lead to fetal complications such as gastroschisis or gastrointestinal bleeding in rare cases. However, these outcomes are less common compared to neonatal pulmonary hypertension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> &nbsp;<strong>Neonatal pulmonary hypertension (HTN):</strong> Exposure to NSAIDs during pregnancy, particularly in the third trimester, can lead to closure of the fetal ductus arteriosus, which can result in neonatal pulmonary hypertension. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Prolonged patency of the ductus arteriosus</strong>: While NSAIDs can affect the ductus arteriosus in utero, their exposure typically leads to its closure rather than prolonged patency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><span style=\"font-size:12.0pt\">: In utero exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) after 32 weeks can lead to neonatal pulmonary hypertension due to the closure of the fetal ductus arteriosus</span></span></span></p>\r\n\r\n<p style=\"margin-left:52px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 2910, Williams Gynecology 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74854,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18724,
      "choices": [
        {
          "id": 74856,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 2</span></span></span></p>"
        },
        {
          "id": 74857,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 2, 3</span></span></span></p>"
        },
        {
          "id": 74858,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 2, 3, 4</span></span></span></p>"
        },
        {
          "id": 74859,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 2, 3, 4, 5</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amongst the following drugs used in Rheumatoid Arthritis which should NOT be used in pregnancy?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Methotrexate</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Leflunomide</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sulfasalazine</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hydroxychloroquine</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Etanercept</span></span></span></li>\r\n</ol>",
      "unique_key": "Q9539889",
      "question_audio": null,
      "question_video": null,
      "map_id": 18493,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A. 1, 2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Among the drugs used for treatment of RA:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Methotrexate and Leflunomide are completely contra-indicated in pregnancy due to their teratogenic effects (Both are category X)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sulfasalazine and Hydroxychloroquine are safe</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Biological DMARDs have revolutionized rheumatoid arthritis treatment. These include the tumor necrosis factor alpha (TNF-&alpha;) inhibitors infliximab, adalimumab, golimumab, certolizumab, and etanercept. Their use in pregnancy is limited, but they appear to be safe for the fetus</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thus, option A; 1,2 i.e. methotrexate and Leflunomide should not be used in pregnancy</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Methotrexate and leflunomide should not be used in pregnancy due to the risk of serious birth defects. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other medications like sulfasalazine, hydroxychloroquine, and etanercept may have different considerations and should be discussed on a case-by-case basis with the patient&rsquo;s healthcare team.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 2911, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 74856,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18725,
      "choices": [
        {
          "id": 74860,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Starting folic acid is just as beneficial now and she should start immediately</span></span></span></p>"
        },
        {
          "id": 74861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The neural tube does not close until 21 weeks so she should start folic acid 4mg/ day in the next few days</span></span></span></p>"
        },
        {
          "id": 74862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The neural tube closes by 6 weeks so folic acid needs to be taken before 6 weeks</span></span></span></p>"
        },
        {
          "id": 74863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Having a prior child with a neural tube defect does not increase her risk so she need not worry</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 29-year-old multigravida presents at 15 weeks gestation to establish prenatal care. The patient&rsquo;s first child had a neural tube defect. The patient did not know that she was pregnant till this week, so she asks you about starting folic acid as she was earlier counselled at the time of her 1<sup>st</sup> pregnancy to take a higher dose of folic acid. Which of the following statements will you mention during counselling?</span></span></span></p>",
      "unique_key": "Q8606770",
      "question_audio": null,
      "question_video": null,
      "map_id": 18494,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. The neural tube closes by 6 weeks so folic acid needs to be taken before 6 weeks</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation of options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Starting folic acid is just as beneficial now and she should start immediately: Incorrect. While starting folic acid at any point during pregnancy is beneficial for overall fetal development, it is particularly critical to take it before the neural tube closes, which occurs by approximately 6 weeks of gestation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: The next few days: Incorrect. The neural tube closes much earlier, around 6 weeks, so it is essential to start folic acid supplementation before that time.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The neural tube closes by 6 weeks, so folic acid needs to be taken before 6 weeks: This statement is correct. Folic acid supplementation is most effective in preventing neural tube defects when taken before conception and during the early weeks of pregnancy when the neural tube is forming.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Having a prior child with a neural tube defect does not increase her risk, so she need not worry: Incorrect. A history of a previous child with a neural tube defect does increase the risk for future pregnancies, and women in this situation should take appropriate precautions, including starting folic acid supplementation before conception.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pre-conceptional Folic Acid should be taken in all women planning to conceive and if not started pre-conceptionally, should be started before 6 weeks of pregnancy (Before the neural tube closes)</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">0.04 mg/ day to low risk</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">4 mg/ day to high risk for neural tube defects &ndash; NTD. Women at high risk for NTD are</span></span></span>\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">H/o previous baby with NTD</span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pre-gestational Diabetes Mellitus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Folic acid deficiency</span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Obesity</span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Epilepsy/ on Antiepileptic Drugs (AED)</span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hemoglobinopathy</span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 491, Williams Obstetrics 26th edition</span></span></strong></p>",
      "correct_choice_id": 74862,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18726,
      "choices": [
        {
          "id": 74864,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For 24 h </span></span></p>"
        },
        {
          "id": 74865,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For 48 h </span></span></p>"
        },
        {
          "id": 74866,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For 24 h if the BP is &gt; 160/100 mmHg</span></span></p>"
        },
        {
          "id": 74867,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continue only if the patient has imminent symptoms of eclampsia</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35y G4 presents to the emergency with eclampsia at 35 weeks. After initial management, MgSO4 is administered as per Pritchard regime, and she is induced. Following delivery, for how long should the maintenance dose of MGSO4 continue?</span></span></span></p>",
      "unique_key": "Q9209898",
      "question_audio": null,
      "question_video": null,
      "map_id": 18495,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A. For 24 h</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">MgSO4 in Eclampsia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Preferred regime is Pritchard&rsquo;s regime: </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">4 g of MgSO4 as a 20% solution @ 1g/ min + 10 g of 50% MgSO4 (5 g in each buttock) f/b maintenance dose of 5 g 50% MgSO4 on alternate buttocks every 4 h till 24 h after delivery/ last convulsion; whichever is later. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If 20% not available, convert 50% to 20% by adding 1.5 times distilled water (1ml of 50% MgSO4 contains 0.5g MgSO4) i.e. to 8ml of 50% MgSO4 + 12ml of distilled water</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Check &ndash; RR, urine output and DTR before administering MgSO4 (Risk of toxicity)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1st to disappear in Mg toxicity: DTR</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other regimes &ndash; Zuspan (Continuous IV regime); higher risk of Mg toxicity if Mg levels unchecked</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Antidote to MgSO4 is Calcium gluconate</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thus, option A) For 24 hrs. post-delivery &nbsp;is correct.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><span style=\"font-size:12.0pt\">: In cases of eclampsia, the maintenance dose of magnesium sulfate (MgSO4) is generally continued for 24 hours after delivery /last convulsion whichever is later as a standard practice to prevent the recurrence of seizures during the postpartum period. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page 1840, Williams Obstetrics 26th edition</span></strong></span></span></p>",
      "correct_choice_id": 74864,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}